Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 314, Issue 1, 2018, Pages L192-L205

  Terryah, Shawn T ^a   Fellner, Robert C ^a   Ahmad, Saira ^a   Moore, Patrick J ^a   Reidel, Boris ^a   Sesma, Juliana I ^b   Kim, Christine S ^a   Garland, Alaina L ^a   Scott, David W ^b   Sabater, Juan R ^c   Carpenter, Jerome ^a   Randell, Scott H ^a   Kesimer, Mehmet ^a   Abraham, William M ^c   Arendshorst, William J ^a   Tarran, Robert ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Spyryx Biosciences Inc   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

18 RESIDUE PEPTIDE; AMILORIDE; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; BPIFA1 PROTEIN, HUMAN; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLYCOPROTEIN; PEPTIDE; PHOSPHOPROTEIN; S18 PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFOCAL MICROSCOPY; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CLEARANCE; LUNG FIBROSIS; MORBIDITY; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUARTZ CRYSTAL MICROBALANCE; RAT; TRACHEA MUCUS; ANIMAL; CELL CULTURE; DRUG EFFECT; EVALUATION STUDY; GENETICS; ION TRANSPORT; LUNG DISEASE; MALE; METABOLISM; PATHOLOGY; RESPIRATORY MUCOSA; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ANIMALS; CELLS, CULTURED; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLYCOPROTEINS; HUMANS; ION TRANSPORT; LUNG DISEASES; MALE; MICE; MICE, TRANSGENIC; PEPTIDES; PHOSPHOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY MUCOSA;

EID: 85043457902     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00546.2016     Document Type: Article

References (54)

1. Ahmad S, Tyrrell J, Walton WG, Tripathy A, Redinbo MR, Tarran R. Short palate, lung, and nasal epithelial clone 1 has antimicrobial and antibiofilm activities against the Burkholderia cepacia complex. Antimicrob Agents Chemother 60: 6003–6012, 2016. doi:10.1128/AAC.00975-16.
2. App EM, King M, Helfesrieder R, Köhler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 141: 605–612, 1990. doi:10.1164/ajrccm/141.3.605.
3. Åstrand AB, Hemmerling M, Root J, Wingren C, Pesic J, Johansson E, Garland AL, Ghosh A, Tarran R. Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition. Am J Physiol Lung Cell Mol Physiol 308: L22–L32, 2015. doi:10.1152/ajplung.00163.2014.
4. Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis. Thorax 51: 126–131, 1996. doi:10.1136/thx.51.2.126.
5. + permeability in cystic fibrosis human primary cell cultures. J Physiol 405: 77–103, 1988. doi:10.1113/jphysiol.1988.sp017322.
6. Bove PF, Grubb BR, Okada SF, Ribeiro CM, Rogers TD, Randell SH, O’Neal WK, Boucher RC. Human alveolar type II cells secrete and absorb liquid in response to local nucleotide signaling. J Biol Chem 285: 34939–34949, 2010. doi:10.1074/jbc.M110.162933.
7. Britto CJ, Cohn L. Bactericidal/permeability-increasing protein fold-containing family member A1 in airway host protection and respiratory disease. Am J Respir Cell Mol Biol 52: 525–534, 2015. doi:10.1165/rcmb. 2014-0297RT.
8. Burrows E, Southern KW, Noone P. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 3: CD005087, 2006. doi:10.1002/14651858.CD005087.pub2.
9. Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc 2: 3247–3256, 2007. doi:10.1038/nprot.2007.454.
10. Donaldson SH, Corcoran TE, Laube BL, Bennett WD. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc 4: 399–405, 2007. doi:10.1513/pats.200703-042BR.
11. Garcia-Caballero A, Rasmussen JE, Gaillard E, Watson MJ, Olsen JC, Donaldson SH, Stutts MJ, Tarran R. SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc Natl Acad Sci USA 106: 11412–11417, 2009. [Erratum in Proc Natl Acad Sci USA 106(35): 15091, 2009. doi:10.1073/pnas.0908688106.]. doi:10. 1073/pnas.0903609106.
12. Garland AL, Walton WG, Coakley RD, Tan CD, Gilmore RC, Hobbs CA, Tripathy A, Clunes LA, Bencharit S, Stutts MJ, Betts L, Redinbo MR, Tarran R. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proc Natl Acad Sci USA 110: 15973–15978, 2013. doi:10.1073/pnas.1311999110.
13. Graeber SY, Zhou-Suckow Z, Schatterny J, Hirtz S, Boucher RC, Mall MA. Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease. Am J Respir Cell Mol Biol 49: 410–417, 2013. doi:10.1165/rcmb.2013-0050OC.
14. Graham A, Hasani A, Alton EW, Martin GP, Marriott C, Hodson ME, Clarke SW, Geddes DM. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 6: 1243–1248, 1993.
15. Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax 71: 284–287, 2016. doi:10.1136/thoraxjnl-2015-207588.
16. Hirsh AJ. Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev 54: 1445–1462, 2002. doi:10.1016/S0169-409X(02)00161-8.
17. Hirsh AJ, Sabater JR, Zamurs A, Smith RT, Paradiso AM, Hopkins S, Abraham WM, Boucher RC. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 311: 929–938, 2004. doi:10.1124/jpet.104.071886.
18. Hobbs CA, Blanchard MG, Alijevic O, Tan CD, Kellenberger S, Bencharit S, Cao R, Kesimer M, Walton WG, Henderson AG, Redinbo MR, Stutts MJ, Tarran R. Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol 305: L990–L1001, 2013. doi:10.1152/ajplung.00103.2013.
19. Hobbs CA, Da Tan C, Tarran R. Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease? J Physiol 591: 4377–4387, 2013. doi:10.1113/jphysiol.2012.240861.
20. Jiang D, Wenzel SE, Wu Q, Bowler RP, Schnell C, Chu HW. Human neutrophil elastase degrades SPLUNC1 and impairs airway epithelial defense against bacteria. PLoS One 8: e64689, 2013. doi:10.1371/journal. pone.0064689.
21. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, MacLaughlin E, Barker P, Nash M, Quittell L, Boucher R, Knowles MR. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 341: 156–162, 1999. doi:10.1056/NEJM199907153410304.
22. Kesimer M, Kirkham S, Pickles RJ, Henderson AG, Alexis NE, Demaria G, Knight D, Thornton DJ, Sheehan JK. Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways? Am J Physiol Lung Cell Mol Physiol 296: L92–L100, 2009. doi:10.1152/ajplung.90388.2008.
23. Kesimer M, Sheehan JK. Analyzing the functions of large glycoconjugates through the dissipative properties of their absorbed layers using the gel-forming mucin MUC5B as an example. Glycobiology 18: 463–472, 2008. doi:10.1093/glycob/cwn024.
24. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher RC. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 322: 1189–1194, 1990. doi:10.1056/NEJM199004263221704.
25. Köhler D, App E, Schmitz-Schumann M, Würtemberger G, Matthys H. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur J Respir Dis Suppl 146: 319–326, 1986.
26. Lai SK, Wang YY, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv Drug Deliv Rev 61: 86–100, 2009. doi:10.1016/j.addr.2008. 09.012.
27. Liu Y, Di ME, Chu HW, Liu X, Wang L, Wenzel S, Di YP. Increased susceptibility to pulmonary Pseudomonas infection in Splunc1 knockout mice. J Immunol 191: 4259–4268, 2013. doi:10.4049/jimmunol.1202340.
28. Livraghi-Butrico A, Grubb BR, Kelly EJ, Wilkinson KJ, Yang H, Geiser M, Randell SH, Boucher RC, O’Neal WK. Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstruction. Physiol Genomics 44: 470–484, 2012. doi:10.1152/physiolgenomics.00185.2011.
29. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol 35: 116–129, 2007. doi:10. 1080/01926230601060025.
30. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS. Thiazolidinone CFTR inhibitor identified by high-through- put screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651–1658, 2002. doi:10.1172/JCI0216112.
31. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26: 966–968, 2010. doi:10. 1093/bioinformatics/btq054.
32. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10: 487–493, 2004. doi:10.1038/nm1028.
33. Mall MA, Button B, Johannesson B, Zhou Z, Livraghi A, Caldwell RA, Schubert SC, Schultz C, O’Neal WK, Pradervand S, Hummler E, Rossier BC, Grubb BR, Boucher RC. Airway surface liquid volume regulation determines different airway phenotypes in liddle compared with βENaC-overexpressing mice. J Biol Chem 285: 26945–26955, 2010. doi:10.1074/jbc.M110.151803.
34. Matalon S, Bartoszewski R, Collawn JF. Role of epithelial sodium channels in the regulation of lung fluid homeostasis. Am J Physiol Lung Cell Mol Physiol 309: L1229–L1238, 2015. doi:10.1152/ajplung.00319.2015.
35. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95: 1005–1015, 1998. doi:10.1016/S0092-8674(00)81724-9.
36. O’Riordan TG, Donn KH, Hodsman P, Ansede JH, Newcomb T, Lewis SA, Flitter WD, White VS, Johnson MR, Montgomery AB, Warnock DG, Boucher RC. Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J Aerosol Med Pulm Drug Deliv 27: 200–208, 2014. doi:10.1089/jamp.2013.1037.
37. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 109: 307–314, 2000. doi:10.1016/S0002-9343(00)00496-4.
38. Puchelle E, Bajolet O, Abély M. Airway mucus in cystic fibrosis. Paediatr Respir Rev 3: 115–119, 2002. doi:10.1016/S1526-0550(02)00005-7.
39. Radicioni G, Cao R, Carpenter J, Ford AA, Wang T, Li L, Kesimer M. The innate immune properties of airway mucosal surfaces are regulated by dynamic interactions between mucins and interacting proteins: the mucin interactome. Mucosal Immunol 9: 1442–1454, 2016. doi:10.1038/mi.2016.27.
40. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 77: 701–726, 2008. doi:10.1146/annurev.biochem.75.103004. 142532.
41. Rollins BM, Garcia-Caballero A, Stutts MJ, Tarran R. SPLUNC1 expression reduces surface levels of the epithelial sodium channel (ENaC) in Xenopus laevis oocytes. Channels (Austin) 4: 255–259, 2010. doi:10. 4161/chan.4.4.12255.
42. Sayeed S, Nistico L, St Croix C, Di YP. Multifunctional role of human SPLUNC1 in Pseudomonas aeruginosa infection. Infect Immun 81: 285– 291, 2013. doi:10.1128/IAI.00500-12.
43. Scherberich JE, Wolf G, Stuckhardt C, Kugler P, Schoeppe W. Characterization and clinical role of glomecular and tubular proteases from human kidney. In: Proteases II: Potential Role in Health and Disease, edited by Hörl WH and Heidland A. Boston, MA: Springer, 1988, p. 275–282. doi:10.1007/978-1-4613-1057-0_32.
44. Tarran R, Boucher RC. Thin-film measurements of airway surface liquid volume/composition and mucus transport rates in vitro. Methods Mol Med 70: 479–492, 2002. doi:10.1385/1-59259-187-6:479.
45. Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Lazarowski ER, Zhang L, Collins PL, Pickles RJ, Fredberg JJ, Boucher RC. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem 280: 35751–35759, 2005. doi:10.1074/jbc.M505832200.
46. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 8: 149–158, 2001. doi:10.1016/S1097-2765(01)00286-6.
47. Tarran R, Redinbo MR. Mammalian short palate lung and nasal epithelial clone 1 (SPLUNC1) in pH-dependent airway hydration. Int J Biochem Cell Biol 52: 130–135, 2014. doi:10.1016/j.biocel.2014.03.002.
48. Thibodeau PH, Butterworth MB. Proteases, cystic fibrosis and the epithelial sodium channel (ENaC). Cell Tissue Res 351: 309–323, 2013. doi:10.1007/s00441-012-1439-z.
49. Vaisman N, Pencharz PB, Corey M, Canny GJ, Hahn E. Energy expenditure of patients with cystic fibrosis. J Pediatr 111: 496–500, 1987. doi:10.1016/S0022-3476(87)80107-5.
50. Walton WG, Ahmad S, Little MS, Kim CS, Tyrrell J, Lin Q, Di YP, Tarran R, Redinbo MR. Structural features essential to the antimicrobial functions of human SPLUNC1. Biochemistry 55: 2979–2991, 2016. doi: 10.1021/acs.biochem.6b00271.
51. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Döring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: 317–325, 2002. doi:10.1172/JCI0213870.
52. Worthington EN, Tarran R. Methods for ASL measurements and mucus transport rates in cell cultures. Methods Mol Biol 742: 77–92, 2011. doi:10.1007/978-1-61779-120-8_5.
53. Zhou Z, Duerr J, Johannesson B, Schubert SC, Treis D, Harm M, Graeber SY, Dalpke A, Schultz C, Mall MA. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 10, Suppl 2: S172–S182, 2011. doi:10.1016/S1569-1993(11)60021-0.
54. Zhou Z, Treis D, Schubert SC, Harm M, Schatterny J, Hirtz S, Duerr J, Boucher RC, Mall MA. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC-overexpressing mice. Am J Respir Crit Care Med 178: 1245–1256, 2008. doi:10.1164/rccm.200803-442OC.